Project Grant R37CA296642
Award Date
12/10/24
Completion Date
11/30/29
Dollars Obligated
$593K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $640,522 Project Grant to The Leland Stanford Junior University to conduct research aimed at identifying microbial-derived proteins that can modulate macrophage function and thereby enhance cancer immunotherapy efficacy. The 5-year project, commencing on May 1, 2025, will utilize high-throughput screening approaches to systematically examine thousands of microbial microproteins and determine their impact on...
This federal Project Grant award, funded by the National Cancer Institute (CFDA 93.396 Cancer Biology Research), supports scientific research to understand the fundamental biological mechanisms underlying non-alcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC). The total award is $2,397,277 with a performance period from September 9, 2024 to August 31, 2029. The research focuses on investigating how metabolic stress and reprogramming via key regulators NRF2 and ATF6 contribute...
The National Cancer Institute (NCI) awarded a $145,336 Project Grant under its Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research, a leading non-profit cancer research organization in New York. The award, effective from March 1, 2025 to February 28, 2027, will support research to determine whether and how metabolically reprogramming hepatic macrophages, a type of immune cell, can overcome the "immune-desert" phenotype of liver cancers...
This $2,678,459 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to Virginia Commonwealth University will support a research program called "Exploiting Therapeutic Vulnerabilities in Hepatocellular Carcinoma (ELEVATE)". The overarching goal is to interrogate molecular changes in hepatocellular carcinoma (HCC), especially in the context of non-alcoholic steatohepatitis (NASH), and develop novel combinatorial treatment approaches. The program...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $282,053 in funding to The Regents of the University of California, San Francisco to support research aimed at understanding the impact of liver disease on myeloid cells and their role in driving resistance to cancer immunotherapy in hepatocellular carcinoma (HCC). The 5-year award, effective March 1, 2025, will enable Dr. Keenan to use single-cell techniques, spatial...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $687,679 to The Trustees of Columbia University in the City of New York to conduct research aimed at understanding and targeting transcriptional master regulators in hepatocellular carcinoma (HCC). The research plan involves computationally establishing HCC transcriptional master regulators, validating their tumor cell-intrinsic functions using...
The National Cancer Institute (NCI) awarded a $148,568.00 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Leland Stanford Junior University (Stanford University). The grant, titled "INTEGRATING HIGHLY MULTIPLEXED IMMUNOFLUORESCENCE WITH LABEL-FREE 2D HYPERSPECTRAL CHEMICAL IMAGING TO INTERROGATE THE COLORECTAL CANCER TUMOR-INVASIVE FRONT," supports research to develop an innovative technology platform that combines highly multiplexed immunofluorescence and...
The National Cancer Institute (NCI) awarded a $107,948 Project Grant through the Cancer Research Manpower (CFDA 93.398) program to The Johns Hopkins University. The grant supports a comparative analysis of the effects of the cytokines M-CSF and GM-CSF on human monocyte metabolic reprogramming and differentiation into tumor-associated macrophage-like cells. The research aims to characterize differences in tumor-associated macrophage (TAM) functional attributes between M-CSF and GM-CSF derived...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop and evaluate novel inhibitors of the NSMASE2 protein as a potential therapeutic strategy to enhance the efficacy of immune checkpoint inhibitors in cancer treatment. The total award amount is $695,916 over a 5-year period starting September 1, 2024. The key products and services to be delivered under this award include: Synthesizing and optimizing PDDC...
This Project Grant award for $648,428 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will support research at Stanford University to investigate the tumor microenvironmental factors that drive the transition from ductal carcinoma in situ (DCIS) to invasive breast cancer. The research aims to identify biomarkers in the extracellular matrix structure, macrophage and fibroblast signaling that are spatially correlated with and causally linked to this...